Global Markets Direct’s, 'Hemoglobinopathies - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hemoglobinopathies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemoglobinopathies. Hemoglobinopathies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Hemoglobinopathies. - A review of the Hemoglobinopathies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hemoglobinopathies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Hemoglobinopathies. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemoglobinopathies pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Hemoglobinopathies - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hemoglobinopathies Overview 6 Therapeutics Development 7 Pipeline Products for Hemoglobinopathies - Overview 7 Pipeline Products for Hemoglobinopathies - Comparative Analysis 8 Hemoglobinopathies - Therapeutics under Development by Companies 9 Hemoglobinopathies - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Hemoglobinopathies - Products under Development by Companies 12 Hemoglobinopathies - Companies Involved in Therapeutics Development 13 Sangamo BioSciences, Inc. 13 Gamida Cell Ltd. 14 Alnylam Pharmaceuticals, Inc. 15 Cancer Therapeutics CRC Pty Ltd 16 Hemoglobinopathies - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 21 Assessment by Therapeutic Class 23 Drug Profiles 25 NiCord - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 ZFP Transcription Factors For Hemoglobinopathies - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 ALN-TMP - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 Drug Targeting PRMT5 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 Drug Targeting Protein Arginine Methyltransferase 5 - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 Hemoglobinopathies - Recent Pipeline Updates 30 Hemoglobinopathies - Product Development Milestones 33 Featured News and Press Releases 33 Dec 08, 2012: Alnylam Pharma Presents New Preclinical Data On RNAi Therapeutics For Treatment Of Hemoglobinopathies At ASH Annual Meeting 2012 33 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables
Number of Products under Development for Hemoglobinopathies, H2 2013 7 Number of Products under Development for Hemoglobinopathies - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Clinical Stage Development, H2 2013 10 Comparative Analysis by Early Stage Development, H2 2013 11 Products under Development by Companies, H2 2013 12 Hemoglobinopathies - Pipeline by Sangamo BioSciences, Inc., H2 2013 13 Hemoglobinopathies - Pipeline by Gamida Cell Ltd., H2 2013 14 Hemoglobinopathies - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2013 15 Hemoglobinopathies - Pipeline by Cancer Therapeutics CRC Pty Ltd, H2 2013 16 Assessment by Monotherapy Products, H2 2013 17 Number of Products by Stage and Target, H2 2013 18 Number of Products by Stage and Mechanism of Action, H2 2013 19 Number of Products by Stage and Route of Administration, H2 2013 20 Number of Products by Stage and Molecule Type, H2 2013 22 Number of Products by Stage and Therapeutic Class, H2 2013 24 Hemoglobinopathies Therapeutics - Recent Pipeline Updates, H2 2013 30
List of Figures
Number of Products under Development for Hemoglobinopathies, H2 2013 7 Number of Products under Development for Hemoglobinopathies - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Early Stage Products, H2 2013 11 Assessment by Monotherapy Products, H2 2013 17 Number of Products by Top 10 Molecule Type, H2 2013 21 Number of Products by Stage and Top 10 Molecule Type, H2 2013 22 Number of Products by Top 10 Therapeutic Class, H2 2013 23 Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 24
Sangamo BioSciences, Inc. Gamida Cell Ltd. Alnylam Pharmaceuticals, Inc. Cancer Therapeutics CRC Pty Ltd